AstraZeneca launches Phase III trial in U.S.Of 30,000 people on the COVID-19 vaccine
AstraZeneca has submitted a Phase III trial of 30,000 patients in the United States on AZD12222, the COVID-19 vaccine it is jointly developing with the University of Oxford and a spin-off company, which will constitute a maximum of the 50,000 participants the company intends to compare.the vaccine on.
AstraZeneca launches Phase III trial in U.S.Of 30,000 people on the COVID-19 vaccine Read More »